Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3862 DLL3 determination and immune milieu characterization in Neuroendocrine Neoplasms (NENs)

Introduction: High DLL3 expression in NENs may be used to activate the immune system by redirecting T cells via bispecific T cell engager (BITE) antibodies.

Conference:

Presenting Author:

Authors: Garcia Alvarez A, Serna G, Hernando Cubero J, Napoli S, Carmona Alonso A,

Keywords: Neuroendocrine, DLL3, Immunotherapy,

#3791 Trends in neuroendocrine-related searches on Google – How famous cases impact on interest of general population

Introduction: General population interest in neuroendocrine tumors (NET) is influenced by mass-media news and awareness campaigns by advocacy and medical groups. Cases of NET in famous people greatly impact conversations about this disease.

Conference:

Presenting Author:

Authors: Hernando Cubero J, Garcia Alvarez A, Roca-Herrera M, Carmona Alonso A, Garcia Burillo A,

Keywords: Google, Trends, Famous,

#3779 177Lu-DOTATATE in advanced neuroendocrine neoplasms of different locations – Data from 552 cases in the SEPTRALU registry

Introduction: Peptide receptor radionuclide therapy (PRRT) is a therapeutic strategy selected via a marker, somatostatin receptor (SSTRs) expression, with activity in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Its role in tumor sites outside the digestive tract remains unclear.

Conference:

Presenting Author:

Authors: Mitjavila Casanovas M, Carmona-Bayonas A, Bello P, de Matias Leralta J, Garcia Burillo A,

Keywords: 177Lu-DOTATATE, lung, neuroendocrine tumor, PRRT, pheochromocytoma, radionuclide therapy,

#3777 The value of the Patient Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) in patients with neuroendocrine tumors (NET) treated with 177Lutetium-DOTATATE (177Lu)

Introduction: The correlation between clinical benefit and toxicity is an unmet need in daily clinical practice. PRO-CTCAE is a questionnaire that allows subjective and detailed symptom reporting directly from patients. This prospective, multicentre study will apply PRO-CTCAE in a cohort of consecutive adult patients with metastatic NET on treatment with 177Lu.

Conference:

Presenting Author: Hernando J

Authors: Carmona Alonso A, Hernando Cubero J, Garcia Alvarez A, Roca-Herrera M, Garcia Burillo A,

Keywords: TNE, 177Lu, PRO-CTCAE,

#2900 Radionuclide Therapy in the Continuum of Care of Neuroendocrine Tumors: Results of the SEPTRALU Study

Introduction: Peptide receptor radionuclide therapy (PRRT, Lu-177-DOTATATE) is safe and effective in neuroendocrine tumors (NET). However, the best sequence of administration is unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Mitjavila Casanovas M, Carmona-Bayonas A, Pubul V, García-Cañamaque L, Aller J,

Keywords: Lu-177-DOTATATE, radionuclide, survival, treatment,